by B2i | Apr 21, 2025 | Press Releases
Company to conduct 1×1 meetings on April 24, 2025GAITHERSBURG, Md., April 21, 2025 — Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) (“Shuttle Pharma” or the “Company”), a discovery and development stage specialty...
by B2i | Apr 10, 2025 | Press Releases
Filing provisional patent application with the USPTO entitled “PSMA-Targeted PARP Inhibitor conjugates for Precision Cancer Therapy” key to advancement of Diagnostic and Therapeutic programs Dr. Alan Kozikowski, internationally acclaimed pioneer in the...
by B2i | Mar 13, 2025 | Press Releases
GAITHERSBURG, Md., March 13, 2025 — Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) (“Shuttle Pharma”), a discovery and development stage specialty pharmaceutical company focused on improving outcomes for cancer patients treated with radiation...
by B2i | Mar 12, 2025 | Press Releases
GAITHERSBURG, Md., March 12, 2025 — Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) (“Shuttle Pharma”), a discovery and development stage specialty pharmaceutical company focused on improving outcomes for cancer patients treated with radiation...
by B2i | Mar 12, 2025 | Press Releases
Dr. Anatoly Dritschilo remains Chairman of the Board and Co-CEO overseeing scientific and clinical trial activitiesGAITHERSBURG, Md., March 12, 2025 — Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) (“Shuttle Pharma” or the...
by B2i | Feb 26, 2025 | Press Releases
GAITHERSBURG, Md., Feb. 26, 2025 — Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) (“Shuttle Pharma” or the “Company”), a discovery and development stage specialty pharmaceutical company focused on improving outcomes for cancer...
